RSS   Newsletter   Contact   Advertise with us

ImmunoGen Q4 revenues up 235%

Christian Fernsby ▼ | February 14, 2020
ImmunoGen today reported financial results for the quarter ended December 31, 2019.
ImmunoGen
ImmunoGen   Total revenues in the fourth quarter increased
Total revenues in the fourth quarter and year ended December 31, 2019 increased to $44.9 million and $82.3 million, respectively, compared to $13.4 million and $53.4 million for the same periods in 2018.

Topics: ImmunoGen

Research and development expenses were $26.1 million for the quarter ended December 31, 2019 compared to $43.7 million for the quarter ended December 31, 2018, and $114.5 million for the year ended December 31, 2019 compared to $174.5 million for the year ended December 31, 2018.

General and administrative expenses were flat at $9.8 million for the fourth quarter of 2019 and 2018, and $38.5 million for the year ended December 31, 2019 compared to $36.7 million for the year ended December 31, 2018.


 

MORE INSIDE POST